Results 141 to 150 of about 26,826 (219)

Enhanced muscle uptake of chemically optimized miR-23b antisense oligonucleotides as lead compounds for myotonic dystrophy type 1. [PDF]

Am J Hum Genet
González-Martínez I, Cerro-Herreros E, Carrascosa-Sàez M, García-Rey A, Piqueras-Losilla D, Colom-Rodrigo A, Moreno N, Chakraborty M, Huguet-Lachon A, González-Barriga A, Naldaiz-Gastesi N, Dehesa M, Díaz-Maqueda A, Barquero N, Varela MA, López de Munain A, Eritja R, Gourdon G, López-Castel A, Pérez-Alonso M, Llamusi B, Artero R.   +21 more
europepmc   +1 more source

Aphasia Leading to the Diagnosis of Myotonic Dystrophy Type 1: A Case Report. [PDF]

Cureus
Maeshima S, Takeda A, Sakurai K, Osawa A, Arai H.   +4 more
europepmc   +1 more source

The blind men and the elephant: recognising the multisystem symptoms of myotonic dystrophy type 1. [PDF]

Orphanet J Rare Dis
Leeuwenberg KE, Bruijnes JE, Karnebeek L, Smulders F, Altena-Rensen S, Gorissen-Brouwers CML, Klinkenberg S, Faber CG, Braakman H, Mul K.   +9 more
europepmc   +1 more source

Cerebrospinal fluid proteomic profiling reveals potential biomarkers and altered pathways in myotonic dystrophy type 1. [PDF]

Front Neurosci
Zafarullah M, Kamali T, Hagerman KA, Ghiglieri L, Duong T, Wang E, Sampson JB, Day JW.   +7 more
europepmc   +1 more source

Myotonic Dystrophy [PDF]

, 2020
openaire   +1 more source

Spectrum of Cancers and Their Prognosis Among Patients With Myotonic Dystrophy.

JAMA Netw Open
Gadalla SM, McNeel TS, Wheeler W, Alsaggaf R, Hameed B, Avantsa S, Ahmadzada M, Pfeiffer RM.   +7 more
europepmc   +1 more source

Targeting Expanded CUG and CTG Repeats as a Therapeutic Approach for Myotonic Dystrophy Type 1 (DM1). [PDF]

ChemMedChem
Richagneux C, Granzhan A.
europepmc   +1 more source

Evaluation of echocardiography monitoring in myotonic dystrophy type 1 patients. [PDF]

Front Cardiovasc Med
Bovenkerk DSH, Janssen CEW, Van den Heuvel FMA, Joosten IBT, Den Uijl D, Van Engelen BGM, Van Kuijk SMJ, Nijveldt R, Evertz R, Faber CG, Vernooy K, Bijvoet GP.   +11 more
europepmc   +1 more source

Establishing biomarkers and clinical endpoints in myotonic dystrophy type 1 (END-DM1): Protocol of an international natural history study. [PDF]

PLoS One
Mul K, Eichinger K, Hung M, Sansone VA, Gagnon C, Subramony S, Roxburgh RH, Hamel J, Statland JM, Elsheikh B, Turner C, Sampson J, Ragole T, Matthews E, Schoser B, Swenson A, Laverty C, Shieh P, Greene EP, Takahashi M, Wicklund M, Dekdebrun J, Raymond J, DeSpain E, Thornton CA, Johnson NE, Myotonic Dystrophy Clinical Research Network.   +26 more
europepmc   +1 more source

Measuring Myotonia: Normative Values and Comparison with Myotonic Dystrophy Type 1. [PDF]

Neurol Int
Sipos A, Árvai M, Varga D, Ruszin-Perecz B, Janszky J, Hajdú N, Pál E.   +6 more
europepmc   +1 more source